<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pharmaessentia Corp. — News on 6ix</title>
<link>https://6ix.com/company/pharmaessentia</link>
<description>Latest news and press releases for Pharmaessentia Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 22 May 2026 14:12:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pharmaessentia" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68367d6578dffbe2df166e34.webp</url>
<title>Pharmaessentia Corp.</title>
<link>https://6ix.com/company/pharmaessentia</link>
</image>
<item>
<title>PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-to-present-new-clinical-data-supporting-the-use-of-ropeginterferon-alfa-2b-in-essential-thrombocythemia-at-asco-and-eha-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-to-present-new-clinical-data-supporting-the-use-of-ropeginterferon-alfa-2b-in-essential-thrombocythemia-at-asco-and-eha-2026</guid>
<pubDate>Fri, 22 May 2026 14:12:00 GMT</pubDate>
<description>BURLINGTON, Mass., May 22, 2026--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced five upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2026 Congress. The ASCO annual meeting will be held May</description>
</item>
<item>
<title>Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials</title>
<link>https://6ix.com/company/pharmaessentia/news/taiwans-representative-to-the-united-states-alexander-tah-ray-yui-visits-pharmaessentias-puerto-rico-facility-alongside-puerto-rico-officials</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/taiwans-representative-to-the-united-states-alexander-tah-ray-yui-visits-pharmaessentias-puerto-rico-facility-alongside-puerto-rico-officials</guid>
<pubDate>Mon, 27 Apr 2026 14:24:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that Taiwan's</description>
</item>
<item>
<title>Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health</title>
<link>https://6ix.com/company/pharmaessentia/news/frankfurt-higher-regional-court-upholds-besremir-arbitral-award-in-favor-of-aop-health</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/frankfurt-higher-regional-court-upholds-besremir-arbitral-award-in-favor-of-aop-health</guid>
<pubDate>Fri, 24 Apr 2026 16:52:00 GMT</pubDate>
<description>VIENNA, April 24, 2026--The Higher Regional Court of Frankfurt upheld the February 2025 ICC arbitral award in favor of AOP Health in its dispute with PharmaEssentia Corp.</description>
</item>
<item>
<title>PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-signs-investment-agreement-for-new-manufacturing-facility-in-puerto-rico</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-signs-investment-agreement-for-new-manufacturing-facility-in-puerto-rico</guid>
<pubDate>Thu, 02 Apr 2026 14:09:00 GMT</pubDate>
<description>BURLINGTON, Mass., April 02, 2026--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that on Thursday, March 26, it signed an investment agreement for a new manufacturing facility in Toa Baja, Puerto Rico. The signing ceremony marks an important milestone in the company’s strategy to establish a dual-site manufacturing network in Taiwan and the United States, strengthening global supply chain resilience and supporting long-term growth.</description>
</item>
<item>
<title>PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-japan-approval-of-high-dose-dosing-regimen-for-besremir</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-japan-approval-of-high-dose-dosing-regimen-for-besremir</guid>
<pubDate>Mon, 02 Mar 2026 15:09:00 GMT</pubDate>
<description>BURLINGTON, Mass., March 02, 2026--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its Japanese subsidiary today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the inclusion of a high-dose dosing regimen for Ropeginterferon alfa-2b in the product label as an alternative dosing schedule.</description>
</item>
<item>
<title>PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-plans-establish-u-150200107</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-plans-establish-u-150200107</guid>
<pubDate>Mon, 09 Feb 2026 15:02:00 GMT</pubDate>
<description>BURLINGTON, Mass., February 09, 2026--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its U.S. subsidiary PharmaEssentia USA Corporation today announced that the global corporate Board of Directors has approved an investment of approximately US$46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico. The planned investment supp</description>
</item>
<item>
<title>PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-updated-nccn-clinical-140000224</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-updated-nccn-clinical-140000224</guid>
<pubDate>Tue, 27 Jan 2026 14:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., January 27, 2026--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. NCCN Clinical Practice Guidelines in Oncology have been updated to include ropeginterferon alfa-2b-njft as a Category 1 preferred treatment option for high-risk patients with esse</description>
</item>
<item>
<title>FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)</title>
<link>https://6ix.com/company/pharmaessentia/news/fda-confirms-pdufa-goal-date-130000506</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/fda-confirms-pdufa-goal-date-130000506</guid>
<pubDate>Tue, 13 Jan 2026 13:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., January 13, 2026--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental Biologics License Application (sBLA) for ropeginterferon alfa-2b-njft for the treatment of adult patient</description>
</item>
<item>
<title>PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-positive-topline-phase-130000226</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-positive-topline-phase-130000226</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., January 12, 2026--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced positive topline results from its Phase 2b EXCEED-ET clinical trial of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia (ET).</description>
</item>
<item>
<title>PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-usa-announces-appointment-jeffrey-131200006</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-usa-announces-appointment-jeffrey-131200006</guid>
<pubDate>Wed, 24 Dec 2025 13:12:00 GMT</pubDate>
<description>BURLINGTON, Mass., December 24, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Jeffrey R. Williams as Independent Director.</description>
</item>
<item>
<title>PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-presentation-j-p-130000455</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-presentation-j-p-130000455</guid>
<pubDate>Mon, 15 Dec 2025 13:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., December 15, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today outlined key accomplishments from 2025 and provided an overview of strategic priorities and anticipated milestones for 2026. The Company also announced its attendance at the 44th Annual J.P. Morgan Healthcare Conferenc</description>
</item>
<item>
<title>PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-publication-phase-3-130000741</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-publication-phase-3-130000741</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., November 24, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that positive results from its pivotal Phase 3 SURPASS-ET clinical trial (NCT04285086) have been published in The Lancet Haematology.</description>
</item>
<item>
<title>PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-usa-announces-appointment-dr-153200730</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-usa-announces-appointment-dr-153200730</guid>
<pubDate>Mon, 10 Nov 2025 15:32:00 GMT</pubDate>
<description>BURLINGTON, Mass., November 10, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Barry Flannelly, Pharm.D., as Independent Director.</description>
</item>
<item>
<title>PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-participate-morgan-stanley-23rd-143200023</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-participate-morgan-stanley-23rd-143200023</guid>
<pubDate>Mon, 18 Aug 2025 14:32:00 GMT</pubDate>
<description>BURLINGTON, Mass., August 18, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Company’s management will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The conference will take place September 8-10, 2025 in New York, NY.</description>
</item>
<item>
<title>PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-presentations-eha-2025-110000736</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-announces-presentations-eha-2025-110000736</guid>
<pubDate>Tue, 03 Jun 2025 11:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., June 03, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will be presenting clinical study results at the 2025 European Hematology Association (EHA) Congress, taking place June 12-15 in Milan, Italy.</description>
</item>
<item>
<title>PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-present-phase-3-surpass-110000330</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-present-phase-3-surpass-110000330</guid>
<pubDate>Tue, 20 May 2025 11:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., May 20, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will present results from the Phase 3 SURPASS-ET clinical trial in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago.</description>
</item>
<item>
<title>PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage</title>
<link>https://6ix.com/company/pharmaessentia/news/pharmaessentia-highlights-availability-besremi-ropeginterferon-160000061</link>
<guid isPermaLink="true">https://6ix.com/company/pharmaessentia/news/pharmaessentia-highlights-availability-besremi-ropeginterferon-160000061</guid>
<pubDate>Tue, 04 Mar 2025 16:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., March 04, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the latest National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2025, January 21, 2025) now highlight the substitution of ropeginterferon alfa-2b-njft (BESREMi®) for treating p</description>
</item>
</channel>
</rss>